nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—CYP2A6—Tamoxifen—pancreatic cancer	0.0484	0.0688	CbGbCtD
Cyclophosphamide—CYP2A6—Fluorouracil—pancreatic cancer	0.0357	0.0507	CbGbCtD
Cyclophosphamide—CYP3A7—Tamoxifen—pancreatic cancer	0.0331	0.047	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.0331	0.047	CbGbCtD
Cyclophosphamide—CYP2B6—Tamoxifen—pancreatic cancer	0.0315	0.0448	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.0254	0.0361	CbGbCtD
Cyclophosphamide—CYP3A7—Irinotecan—pancreatic cancer	0.0254	0.0361	CbGbCtD
Cyclophosphamide—CYP3A5—Tamoxifen—pancreatic cancer	0.0248	0.0353	CbGbCtD
Cyclophosphamide—CYP2B6—Irinotecan—pancreatic cancer	0.0242	0.0344	CbGbCtD
Cyclophosphamide—CYP2C8—Tamoxifen—pancreatic cancer	0.0239	0.0339	CbGbCtD
Cyclophosphamide—CYP3A5—Erlotinib—pancreatic cancer	0.0211	0.03	CbGbCtD
Cyclophosphamide—CYP2C8—Erlotinib—pancreatic cancer	0.0203	0.0288	CbGbCtD
Cyclophosphamide—CYP2C19—Tamoxifen—pancreatic cancer	0.02	0.0284	CbGbCtD
Cyclophosphamide—CYP3A5—Irinotecan—pancreatic cancer	0.0191	0.0271	CbGbCtD
Cyclophosphamide—CYP3A7—Docetaxel—pancreatic cancer	0.0186	0.0264	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.0186	0.0264	CbGbCtD
Cyclophosphamide—CYP3A7—Sunitinib—pancreatic cancer	0.0185	0.0263	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.0185	0.0263	CbGbCtD
Cyclophosphamide—CYP2C8—Fluorouracil—pancreatic cancer	0.0176	0.025	CbGbCtD
Cyclophosphamide—CYP2C9—Tamoxifen—pancreatic cancer	0.0166	0.0236	CbGbCtD
Cyclophosphamide—ABCB1—Tamoxifen—pancreatic cancer	0.0162	0.0229	CbGbCtD
Cyclophosphamide—CYP2D6—Tamoxifen—pancreatic cancer	0.0152	0.0216	CbGbCtD
Cyclophosphamide—CYP3A5—Docetaxel—pancreatic cancer	0.014	0.0198	CbGbCtD
Cyclophosphamide—ABCB1—Gemcitabine—pancreatic cancer	0.0139	0.0198	CbGbCtD
Cyclophosphamide—CYP3A5—Sunitinib—pancreatic cancer	0.0139	0.0197	CbGbCtD
Cyclophosphamide—ABCB1—Erlotinib—pancreatic cancer	0.0137	0.0195	CbGbCtD
Cyclophosphamide—CYP2B6—Doxorubicin—pancreatic cancer	0.0132	0.0188	CbGbCtD
Cyclophosphamide—CYP2D6—Erlotinib—pancreatic cancer	0.0129	0.0184	CbGbCtD
Cyclophosphamide—ABCB1—Irinotecan—pancreatic cancer	0.0124	0.0176	CbGbCtD
Cyclophosphamide—CYP2C9—Fluorouracil—pancreatic cancer	0.0123	0.0174	CbGbCtD
Cyclophosphamide—CYP3A4—Tamoxifen—pancreatic cancer	0.00968	0.0137	CbGbCtD
Cyclophosphamide—ABCB1—Docetaxel—pancreatic cancer	0.00909	0.0129	CbGbCtD
Cyclophosphamide—ABCB1—Sunitinib—pancreatic cancer	0.00905	0.0129	CbGbCtD
Cyclophosphamide—CYP3A4—Erlotinib—pancreatic cancer	0.00823	0.0117	CbGbCtD
Cyclophosphamide—CYP3A4—Irinotecan—pancreatic cancer	0.00743	0.0106	CbGbCtD
Cyclophosphamide—ABCB1—Doxorubicin—pancreatic cancer	0.00678	0.00963	CbGbCtD
Cyclophosphamide—CYP2D6—Doxorubicin—pancreatic cancer	0.00638	0.00907	CbGbCtD
Cyclophosphamide—CYP3A4—Docetaxel—pancreatic cancer	0.00545	0.00774	CbGbCtD
Cyclophosphamide—CYP3A4—Sunitinib—pancreatic cancer	0.00542	0.0077	CbGbCtD
Cyclophosphamide—CYP3A4—Doxorubicin—pancreatic cancer	0.00406	0.00577	CbGbCtD
Cyclophosphamide—Asthenia—Sunitinib—pancreatic cancer	9.17e-05	0.00031	CcSEcCtD
Cyclophosphamide—Decreased appetite—Irinotecan—pancreatic cancer	9.15e-05	0.000309	CcSEcCtD
Cyclophosphamide—Arrhythmia—Docetaxel—pancreatic cancer	9.15e-05	0.000309	CcSEcCtD
Cyclophosphamide—Dyspnoea—Gemcitabine—pancreatic cancer	9.14e-05	0.000309	CcSEcCtD
Cyclophosphamide—Fatigue—Irinotecan—pancreatic cancer	9.08e-05	0.000307	CcSEcCtD
Cyclophosphamide—Paraesthesia—Fluorouracil—pancreatic cancer	9.05e-05	0.000306	CcSEcCtD
Cyclophosphamide—Alopecia—Docetaxel—pancreatic cancer	9.05e-05	0.000306	CcSEcCtD
Cyclophosphamide—Pruritus—Sunitinib—pancreatic cancer	9.04e-05	0.000305	CcSEcCtD
Cyclophosphamide—Constipation—Irinotecan—pancreatic cancer	9e-05	0.000304	CcSEcCtD
Cyclophosphamide—Pain—Irinotecan—pancreatic cancer	9e-05	0.000304	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	8.99e-05	0.000304	CcSEcCtD
Cyclophosphamide—Dyspnoea—Fluorouracil—pancreatic cancer	8.99e-05	0.000304	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Epirubicin—pancreatic cancer	8.93e-05	0.000302	CcSEcCtD
Cyclophosphamide—Erythema—Docetaxel—pancreatic cancer	8.92e-05	0.000301	CcSEcCtD
Cyclophosphamide—Decreased appetite—Gemcitabine—pancreatic cancer	8.91e-05	0.000301	CcSEcCtD
Cyclophosphamide—Nausea—Tamoxifen—pancreatic cancer	8.86e-05	0.000299	CcSEcCtD
Cyclophosphamide—Fatigue—Gemcitabine—pancreatic cancer	8.84e-05	0.000299	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Doxorubicin—pancreatic cancer	8.79e-05	0.000297	CcSEcCtD
Cyclophosphamide—Pain—Gemcitabine—pancreatic cancer	8.77e-05	0.000296	CcSEcCtD
Cyclophosphamide—Constipation—Gemcitabine—pancreatic cancer	8.77e-05	0.000296	CcSEcCtD
Cyclophosphamide—Nausea—Erlotinib—pancreatic cancer	8.77e-05	0.000296	CcSEcCtD
Cyclophosphamide—Decreased appetite—Fluorouracil—pancreatic cancer	8.76e-05	0.000296	CcSEcCtD
Cyclophosphamide—Diarrhoea—Sunitinib—pancreatic cancer	8.74e-05	0.000295	CcSEcCtD
Cyclophosphamide—Dysgeusia—Docetaxel—pancreatic cancer	8.73e-05	0.000295	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Irinotecan—pancreatic cancer	8.68e-05	0.000293	CcSEcCtD
Cyclophosphamide—Pain—Fluorouracil—pancreatic cancer	8.62e-05	0.000291	CcSEcCtD
Cyclophosphamide—Muscle spasms—Docetaxel—pancreatic cancer	8.57e-05	0.00029	CcSEcCtD
Cyclophosphamide—Dizziness—Sunitinib—pancreatic cancer	8.45e-05	0.000285	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Gemcitabine—pancreatic cancer	8.45e-05	0.000285	CcSEcCtD
Cyclophosphamide—Body temperature increased—Irinotecan—pancreatic cancer	8.32e-05	0.000281	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	8.32e-05	0.000281	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Fluorouracil—pancreatic cancer	8.31e-05	0.000281	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Doxorubicin—pancreatic cancer	8.26e-05	0.000279	CcSEcCtD
Cyclophosphamide—Anaemia—Docetaxel—pancreatic cancer	8.24e-05	0.000278	CcSEcCtD
Cyclophosphamide—Pancytopenia—Epirubicin—pancreatic cancer	8.2e-05	0.000277	CcSEcCtD
Cyclophosphamide—Vomiting—Sunitinib—pancreatic cancer	8.13e-05	0.000274	CcSEcCtD
Cyclophosphamide—Body temperature increased—Gemcitabine—pancreatic cancer	8.11e-05	0.000274	CcSEcCtD
Cyclophosphamide—Rash—Sunitinib—pancreatic cancer	8.06e-05	0.000272	CcSEcCtD
Cyclophosphamide—Dermatitis—Sunitinib—pancreatic cancer	8.05e-05	0.000272	CcSEcCtD
Cyclophosphamide—Urticaria—Fluorouracil—pancreatic cancer	8.01e-05	0.000271	CcSEcCtD
Cyclophosphamide—Headache—Sunitinib—pancreatic cancer	8.01e-05	0.00027	CcSEcCtD
Cyclophosphamide—Leukopenia—Docetaxel—pancreatic cancer	7.98e-05	0.00027	CcSEcCtD
Cyclophosphamide—Body temperature increased—Fluorouracil—pancreatic cancer	7.97e-05	0.000269	CcSEcCtD
Cyclophosphamide—Palpitations—Docetaxel—pancreatic cancer	7.88e-05	0.000266	CcSEcCtD
Cyclophosphamide—Weight increased—Epirubicin—pancreatic cancer	7.86e-05	0.000265	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Epirubicin—pancreatic cancer	7.79e-05	0.000263	CcSEcCtD
Cyclophosphamide—Cough—Docetaxel—pancreatic cancer	7.78e-05	0.000263	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Irinotecan—pancreatic cancer	7.76e-05	0.000262	CcSEcCtD
Cyclophosphamide—Pneumonia—Epirubicin—pancreatic cancer	7.74e-05	0.000261	CcSEcCtD
Cyclophosphamide—Convulsion—Docetaxel—pancreatic cancer	7.73e-05	0.000261	CcSEcCtD
Cyclophosphamide—Hypertension—Docetaxel—pancreatic cancer	7.7e-05	0.00026	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	7.63e-05	0.000258	CcSEcCtD
Cyclophosphamide—Chest pain—Docetaxel—pancreatic cancer	7.59e-05	0.000256	CcSEcCtD
Cyclophosphamide—Myalgia—Docetaxel—pancreatic cancer	7.59e-05	0.000256	CcSEcCtD
Cyclophosphamide—Arthralgia—Docetaxel—pancreatic cancer	7.59e-05	0.000256	CcSEcCtD
Cyclophosphamide—Nausea—Sunitinib—pancreatic cancer	7.59e-05	0.000256	CcSEcCtD
Cyclophosphamide—Pancytopenia—Doxorubicin—pancreatic cancer	7.58e-05	0.000256	CcSEcCtD
Cyclophosphamide—Renal failure—Epirubicin—pancreatic cancer	7.57e-05	0.000255	CcSEcCtD
Cyclophosphamide—Asthenia—Irinotecan—pancreatic cancer	7.55e-05	0.000255	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Epirubicin—pancreatic cancer	7.54e-05	0.000255	CcSEcCtD
Cyclophosphamide—Stomatitis—Epirubicin—pancreatic cancer	7.5e-05	0.000253	CcSEcCtD
Cyclophosphamide—Jaundice—Epirubicin—pancreatic cancer	7.5e-05	0.000253	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Epirubicin—pancreatic cancer	7.48e-05	0.000253	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Fluorouracil—pancreatic cancer	7.43e-05	0.000251	CcSEcCtD
Cyclophosphamide—Sweating—Epirubicin—pancreatic cancer	7.38e-05	0.000249	CcSEcCtD
Cyclophosphamide—Asthenia—Gemcitabine—pancreatic cancer	7.36e-05	0.000248	CcSEcCtD
Cyclophosphamide—Haematuria—Epirubicin—pancreatic cancer	7.34e-05	0.000248	CcSEcCtD
Cyclophosphamide—Confusional state—Docetaxel—pancreatic cancer	7.34e-05	0.000248	CcSEcCtD
Cyclophosphamide—Oedema—Docetaxel—pancreatic cancer	7.28e-05	0.000246	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Docetaxel—pancreatic cancer	7.28e-05	0.000246	CcSEcCtD
Cyclophosphamide—Weight increased—Doxorubicin—pancreatic cancer	7.27e-05	0.000245	CcSEcCtD
Cyclophosphamide—Pruritus—Gemcitabine—pancreatic cancer	7.26e-05	0.000245	CcSEcCtD
Cyclophosphamide—Infection—Docetaxel—pancreatic cancer	7.23e-05	0.000244	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Doxorubicin—pancreatic cancer	7.2e-05	0.000243	CcSEcCtD
Cyclophosphamide—Diarrhoea—Irinotecan—pancreatic cancer	7.2e-05	0.000243	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Epirubicin—pancreatic cancer	7.18e-05	0.000243	CcSEcCtD
Cyclophosphamide—Pneumonia—Doxorubicin—pancreatic cancer	7.16e-05	0.000242	CcSEcCtD
Cyclophosphamide—Shock—Docetaxel—pancreatic cancer	7.16e-05	0.000242	CcSEcCtD
Cyclophosphamide—Pruritus—Fluorouracil—pancreatic cancer	7.13e-05	0.000241	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Docetaxel—pancreatic cancer	7.13e-05	0.000241	CcSEcCtD
Cyclophosphamide—Tachycardia—Docetaxel—pancreatic cancer	7.1e-05	0.00024	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	7.06e-05	0.000238	CcSEcCtD
Cyclophosphamide—Bradycardia—Epirubicin—pancreatic cancer	7.03e-05	0.000238	CcSEcCtD
Cyclophosphamide—Diarrhoea—Gemcitabine—pancreatic cancer	7.02e-05	0.000237	CcSEcCtD
Cyclophosphamide—Renal failure—Doxorubicin—pancreatic cancer	7e-05	0.000236	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Doxorubicin—pancreatic cancer	6.98e-05	0.000236	CcSEcCtD
Cyclophosphamide—Dizziness—Irinotecan—pancreatic cancer	6.96e-05	0.000235	CcSEcCtD
Cyclophosphamide—Haemoglobin—Epirubicin—pancreatic cancer	6.94e-05	0.000235	CcSEcCtD
Cyclophosphamide—Jaundice—Doxorubicin—pancreatic cancer	6.94e-05	0.000234	CcSEcCtD
Cyclophosphamide—Stomatitis—Doxorubicin—pancreatic cancer	6.94e-05	0.000234	CcSEcCtD
Cyclophosphamide—Anorexia—Docetaxel—pancreatic cancer	6.94e-05	0.000234	CcSEcCtD
Cyclophosphamide—Rhinitis—Epirubicin—pancreatic cancer	6.93e-05	0.000234	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Doxorubicin—pancreatic cancer	6.92e-05	0.000234	CcSEcCtD
Cyclophosphamide—Haemorrhage—Epirubicin—pancreatic cancer	6.91e-05	0.000233	CcSEcCtD
Cyclophosphamide—Hepatitis—Epirubicin—pancreatic cancer	6.91e-05	0.000233	CcSEcCtD
Cyclophosphamide—Diarrhoea—Fluorouracil—pancreatic cancer	6.9e-05	0.000233	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Epirubicin—pancreatic cancer	6.87e-05	0.000232	CcSEcCtD
Cyclophosphamide—Sweating—Doxorubicin—pancreatic cancer	6.83e-05	0.000231	CcSEcCtD
Cyclophosphamide—Hypotension—Docetaxel—pancreatic cancer	6.8e-05	0.00023	CcSEcCtD
Cyclophosphamide—Haematuria—Doxorubicin—pancreatic cancer	6.79e-05	0.000229	CcSEcCtD
Cyclophosphamide—Vomiting—Irinotecan—pancreatic cancer	6.69e-05	0.000226	CcSEcCtD
Cyclophosphamide—Dizziness—Fluorouracil—pancreatic cancer	6.67e-05	0.000225	CcSEcCtD
Cyclophosphamide—Visual impairment—Epirubicin—pancreatic cancer	6.66e-05	0.000225	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Doxorubicin—pancreatic cancer	6.65e-05	0.000224	CcSEcCtD
Cyclophosphamide—Rash—Irinotecan—pancreatic cancer	6.64e-05	0.000224	CcSEcCtD
Cyclophosphamide—Dermatitis—Irinotecan—pancreatic cancer	6.63e-05	0.000224	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	6.63e-05	0.000224	CcSEcCtD
Cyclophosphamide—Headache—Irinotecan—pancreatic cancer	6.6e-05	0.000223	CcSEcCtD
Cyclophosphamide—Paraesthesia—Docetaxel—pancreatic cancer	6.53e-05	0.000221	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Epirubicin—pancreatic cancer	6.53e-05	0.000221	CcSEcCtD
Cyclophosphamide—Vomiting—Gemcitabine—pancreatic cancer	6.52e-05	0.00022	CcSEcCtD
Cyclophosphamide—Bradycardia—Doxorubicin—pancreatic cancer	6.51e-05	0.00022	CcSEcCtD
Cyclophosphamide—Dyspnoea—Docetaxel—pancreatic cancer	6.49e-05	0.000219	CcSEcCtD
Cyclophosphamide—Rash—Gemcitabine—pancreatic cancer	6.47e-05	0.000218	CcSEcCtD
Cyclophosphamide—Dermatitis—Gemcitabine—pancreatic cancer	6.46e-05	0.000218	CcSEcCtD
Cyclophosphamide—Tinnitus—Epirubicin—pancreatic cancer	6.44e-05	0.000218	CcSEcCtD
Cyclophosphamide—Haemoglobin—Doxorubicin—pancreatic cancer	6.43e-05	0.000217	CcSEcCtD
Cyclophosphamide—Headache—Gemcitabine—pancreatic cancer	6.42e-05	0.000217	CcSEcCtD
Cyclophosphamide—Flushing—Epirubicin—pancreatic cancer	6.41e-05	0.000217	CcSEcCtD
Cyclophosphamide—Vomiting—Fluorouracil—pancreatic cancer	6.41e-05	0.000217	CcSEcCtD
Cyclophosphamide—Rhinitis—Doxorubicin—pancreatic cancer	6.41e-05	0.000216	CcSEcCtD
Cyclophosphamide—Hepatitis—Doxorubicin—pancreatic cancer	6.39e-05	0.000216	CcSEcCtD
Cyclophosphamide—Haemorrhage—Doxorubicin—pancreatic cancer	6.39e-05	0.000216	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Doxorubicin—pancreatic cancer	6.36e-05	0.000215	CcSEcCtD
Cyclophosphamide—Rash—Fluorouracil—pancreatic cancer	6.36e-05	0.000215	CcSEcCtD
Cyclophosphamide—Dermatitis—Fluorouracil—pancreatic cancer	6.35e-05	0.000215	CcSEcCtD
Cyclophosphamide—Decreased appetite—Docetaxel—pancreatic cancer	6.33e-05	0.000214	CcSEcCtD
Cyclophosphamide—Headache—Fluorouracil—pancreatic cancer	6.32e-05	0.000213	CcSEcCtD
Cyclophosphamide—Fatigue—Docetaxel—pancreatic cancer	6.27e-05	0.000212	CcSEcCtD
Cyclophosphamide—Nausea—Irinotecan—pancreatic cancer	6.25e-05	0.000211	CcSEcCtD
Cyclophosphamide—Constipation—Docetaxel—pancreatic cancer	6.22e-05	0.00021	CcSEcCtD
Cyclophosphamide—Pain—Docetaxel—pancreatic cancer	6.22e-05	0.00021	CcSEcCtD
Cyclophosphamide—Chills—Epirubicin—pancreatic cancer	6.2e-05	0.000209	CcSEcCtD
Cyclophosphamide—Arrhythmia—Epirubicin—pancreatic cancer	6.17e-05	0.000208	CcSEcCtD
Cyclophosphamide—Visual impairment—Doxorubicin—pancreatic cancer	6.16e-05	0.000208	CcSEcCtD
Cyclophosphamide—Alopecia—Epirubicin—pancreatic cancer	6.11e-05	0.000206	CcSEcCtD
Cyclophosphamide—Nausea—Gemcitabine—pancreatic cancer	6.09e-05	0.000206	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Doxorubicin—pancreatic cancer	6.04e-05	0.000204	CcSEcCtD
Cyclophosphamide—Erythema—Epirubicin—pancreatic cancer	6.01e-05	0.000203	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Docetaxel—pancreatic cancer	6e-05	0.000203	CcSEcCtD
Cyclophosphamide—Nausea—Fluorouracil—pancreatic cancer	5.99e-05	0.000202	CcSEcCtD
Cyclophosphamide—Tinnitus—Doxorubicin—pancreatic cancer	5.96e-05	0.000201	CcSEcCtD
Cyclophosphamide—Flushing—Doxorubicin—pancreatic cancer	5.93e-05	0.0002	CcSEcCtD
Cyclophosphamide—Dysgeusia—Epirubicin—pancreatic cancer	5.89e-05	0.000199	CcSEcCtD
Cyclophosphamide—Muscle spasms—Epirubicin—pancreatic cancer	5.78e-05	0.000195	CcSEcCtD
Cyclophosphamide—Body temperature increased—Docetaxel—pancreatic cancer	5.75e-05	0.000194	CcSEcCtD
Cyclophosphamide—Chills—Doxorubicin—pancreatic cancer	5.74e-05	0.000194	CcSEcCtD
Cyclophosphamide—Arrhythmia—Doxorubicin—pancreatic cancer	5.71e-05	0.000193	CcSEcCtD
Cyclophosphamide—Vision blurred—Epirubicin—pancreatic cancer	5.67e-05	0.000191	CcSEcCtD
Cyclophosphamide—Alopecia—Doxorubicin—pancreatic cancer	5.65e-05	0.000191	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Epirubicin—pancreatic cancer	5.58e-05	0.000188	CcSEcCtD
Cyclophosphamide—Erythema—Doxorubicin—pancreatic cancer	5.56e-05	0.000188	CcSEcCtD
Cyclophosphamide—Anaemia—Epirubicin—pancreatic cancer	5.56e-05	0.000188	CcSEcCtD
Cyclophosphamide—Agitation—Epirubicin—pancreatic cancer	5.53e-05	0.000187	CcSEcCtD
Cyclophosphamide—Dysgeusia—Doxorubicin—pancreatic cancer	5.45e-05	0.000184	CcSEcCtD
Cyclophosphamide—Malaise—Epirubicin—pancreatic cancer	5.42e-05	0.000183	CcSEcCtD
Cyclophosphamide—Leukopenia—Epirubicin—pancreatic cancer	5.38e-05	0.000182	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Docetaxel—pancreatic cancer	5.36e-05	0.000181	CcSEcCtD
Cyclophosphamide—Muscle spasms—Doxorubicin—pancreatic cancer	5.35e-05	0.000181	CcSEcCtD
Cyclophosphamide—Palpitations—Epirubicin—pancreatic cancer	5.31e-05	0.000179	CcSEcCtD
Cyclophosphamide—Cough—Epirubicin—pancreatic cancer	5.25e-05	0.000177	CcSEcCtD
Cyclophosphamide—Vision blurred—Doxorubicin—pancreatic cancer	5.24e-05	0.000177	CcSEcCtD
Cyclophosphamide—Asthenia—Docetaxel—pancreatic cancer	5.22e-05	0.000176	CcSEcCtD
Cyclophosphamide—Convulsion—Epirubicin—pancreatic cancer	5.21e-05	0.000176	CcSEcCtD
Cyclophosphamide—Hypertension—Epirubicin—pancreatic cancer	5.19e-05	0.000175	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Doxorubicin—pancreatic cancer	5.16e-05	0.000174	CcSEcCtD
Cyclophosphamide—Pruritus—Docetaxel—pancreatic cancer	5.15e-05	0.000174	CcSEcCtD
Cyclophosphamide—Anaemia—Doxorubicin—pancreatic cancer	5.14e-05	0.000174	CcSEcCtD
Cyclophosphamide—Myalgia—Epirubicin—pancreatic cancer	5.12e-05	0.000173	CcSEcCtD
Cyclophosphamide—Chest pain—Epirubicin—pancreatic cancer	5.12e-05	0.000173	CcSEcCtD
Cyclophosphamide—Arthralgia—Epirubicin—pancreatic cancer	5.12e-05	0.000173	CcSEcCtD
Cyclophosphamide—Agitation—Doxorubicin—pancreatic cancer	5.11e-05	0.000173	CcSEcCtD
Cyclophosphamide—Discomfort—Epirubicin—pancreatic cancer	5.06e-05	0.000171	CcSEcCtD
Cyclophosphamide—Malaise—Doxorubicin—pancreatic cancer	5.02e-05	0.000169	CcSEcCtD
Cyclophosphamide—Leukopenia—Doxorubicin—pancreatic cancer	4.98e-05	0.000168	CcSEcCtD
Cyclophosphamide—Diarrhoea—Docetaxel—pancreatic cancer	4.98e-05	0.000168	CcSEcCtD
Cyclophosphamide—Confusional state—Epirubicin—pancreatic cancer	4.95e-05	0.000167	CcSEcCtD
Cyclophosphamide—Palpitations—Doxorubicin—pancreatic cancer	4.92e-05	0.000166	CcSEcCtD
Cyclophosphamide—Oedema—Epirubicin—pancreatic cancer	4.91e-05	0.000166	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Epirubicin—pancreatic cancer	4.91e-05	0.000166	CcSEcCtD
Cyclophosphamide—Infection—Epirubicin—pancreatic cancer	4.88e-05	0.000165	CcSEcCtD
Cyclophosphamide—Cough—Doxorubicin—pancreatic cancer	4.86e-05	0.000164	CcSEcCtD
Cyclophosphamide—Shock—Epirubicin—pancreatic cancer	4.83e-05	0.000163	CcSEcCtD
Cyclophosphamide—Convulsion—Doxorubicin—pancreatic cancer	4.82e-05	0.000163	CcSEcCtD
Cyclophosphamide—Dizziness—Docetaxel—pancreatic cancer	4.81e-05	0.000163	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Epirubicin—pancreatic cancer	4.81e-05	0.000162	CcSEcCtD
Cyclophosphamide—Hypertension—Doxorubicin—pancreatic cancer	4.8e-05	0.000162	CcSEcCtD
Cyclophosphamide—Tachycardia—Epirubicin—pancreatic cancer	4.79e-05	0.000162	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Epirubicin—pancreatic cancer	4.75e-05	0.00016	CcSEcCtD
Cyclophosphamide—Arthralgia—Doxorubicin—pancreatic cancer	4.74e-05	0.00016	CcSEcCtD
Cyclophosphamide—Chest pain—Doxorubicin—pancreatic cancer	4.74e-05	0.00016	CcSEcCtD
Cyclophosphamide—Myalgia—Doxorubicin—pancreatic cancer	4.74e-05	0.00016	CcSEcCtD
Cyclophosphamide—Discomfort—Doxorubicin—pancreatic cancer	4.68e-05	0.000158	CcSEcCtD
Cyclophosphamide—Anorexia—Epirubicin—pancreatic cancer	4.68e-05	0.000158	CcSEcCtD
Cyclophosphamide—Vomiting—Docetaxel—pancreatic cancer	4.63e-05	0.000156	CcSEcCtD
Cyclophosphamide—Rash—Docetaxel—pancreatic cancer	4.59e-05	0.000155	CcSEcCtD
Cyclophosphamide—Hypotension—Epirubicin—pancreatic cancer	4.59e-05	0.000155	CcSEcCtD
Cyclophosphamide—Dermatitis—Docetaxel—pancreatic cancer	4.58e-05	0.000155	CcSEcCtD
Cyclophosphamide—Confusional state—Doxorubicin—pancreatic cancer	4.58e-05	0.000155	CcSEcCtD
Cyclophosphamide—Headache—Docetaxel—pancreatic cancer	4.56e-05	0.000154	CcSEcCtD
Cyclophosphamide—Oedema—Doxorubicin—pancreatic cancer	4.54e-05	0.000153	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Doxorubicin—pancreatic cancer	4.54e-05	0.000153	CcSEcCtD
Cyclophosphamide—Infection—Doxorubicin—pancreatic cancer	4.51e-05	0.000152	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	4.47e-05	0.000151	CcSEcCtD
Cyclophosphamide—Shock—Doxorubicin—pancreatic cancer	4.47e-05	0.000151	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Doxorubicin—pancreatic cancer	4.45e-05	0.00015	CcSEcCtD
Cyclophosphamide—Tachycardia—Doxorubicin—pancreatic cancer	4.43e-05	0.00015	CcSEcCtD
Cyclophosphamide—Paraesthesia—Epirubicin—pancreatic cancer	4.41e-05	0.000149	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Doxorubicin—pancreatic cancer	4.39e-05	0.000148	CcSEcCtD
Cyclophosphamide—Dyspnoea—Epirubicin—pancreatic cancer	4.38e-05	0.000148	CcSEcCtD
Cyclophosphamide—Anorexia—Doxorubicin—pancreatic cancer	4.33e-05	0.000146	CcSEcCtD
Cyclophosphamide—Nausea—Docetaxel—pancreatic cancer	4.32e-05	0.000146	CcSEcCtD
Cyclophosphamide—Decreased appetite—Epirubicin—pancreatic cancer	4.27e-05	0.000144	CcSEcCtD
Cyclophosphamide—Hypotension—Doxorubicin—pancreatic cancer	4.24e-05	0.000143	CcSEcCtD
Cyclophosphamide—Fatigue—Epirubicin—pancreatic cancer	4.23e-05	0.000143	CcSEcCtD
Cyclophosphamide—Pain—Epirubicin—pancreatic cancer	4.2e-05	0.000142	CcSEcCtD
Cyclophosphamide—Constipation—Epirubicin—pancreatic cancer	4.2e-05	0.000142	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	4.14e-05	0.00014	CcSEcCtD
Cyclophosphamide—Paraesthesia—Doxorubicin—pancreatic cancer	4.08e-05	0.000138	CcSEcCtD
Cyclophosphamide—Dyspnoea—Doxorubicin—pancreatic cancer	4.05e-05	0.000137	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Epirubicin—pancreatic cancer	4.04e-05	0.000137	CcSEcCtD
Cyclophosphamide—Decreased appetite—Doxorubicin—pancreatic cancer	3.95e-05	0.000133	CcSEcCtD
Cyclophosphamide—Fatigue—Doxorubicin—pancreatic cancer	3.92e-05	0.000132	CcSEcCtD
Cyclophosphamide—Urticaria—Epirubicin—pancreatic cancer	3.9e-05	0.000132	CcSEcCtD
Cyclophosphamide—Constipation—Doxorubicin—pancreatic cancer	3.88e-05	0.000131	CcSEcCtD
Cyclophosphamide—Pain—Doxorubicin—pancreatic cancer	3.88e-05	0.000131	CcSEcCtD
Cyclophosphamide—Body temperature increased—Epirubicin—pancreatic cancer	3.88e-05	0.000131	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Doxorubicin—pancreatic cancer	3.74e-05	0.000126	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Epirubicin—pancreatic cancer	3.62e-05	0.000122	CcSEcCtD
Cyclophosphamide—Urticaria—Doxorubicin—pancreatic cancer	3.61e-05	0.000122	CcSEcCtD
Cyclophosphamide—Body temperature increased—Doxorubicin—pancreatic cancer	3.59e-05	0.000121	CcSEcCtD
Cyclophosphamide—Asthenia—Epirubicin—pancreatic cancer	3.52e-05	0.000119	CcSEcCtD
Cyclophosphamide—Pruritus—Epirubicin—pancreatic cancer	3.47e-05	0.000117	CcSEcCtD
Cyclophosphamide—Diarrhoea—Epirubicin—pancreatic cancer	3.36e-05	0.000113	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Doxorubicin—pancreatic cancer	3.35e-05	0.000113	CcSEcCtD
Cyclophosphamide—Asthenia—Doxorubicin—pancreatic cancer	3.26e-05	0.00011	CcSEcCtD
Cyclophosphamide—Dizziness—Epirubicin—pancreatic cancer	3.25e-05	0.00011	CcSEcCtD
Cyclophosphamide—Pruritus—Doxorubicin—pancreatic cancer	3.21e-05	0.000109	CcSEcCtD
Cyclophosphamide—Vomiting—Epirubicin—pancreatic cancer	3.12e-05	0.000105	CcSEcCtD
Cyclophosphamide—Diarrhoea—Doxorubicin—pancreatic cancer	3.11e-05	0.000105	CcSEcCtD
Cyclophosphamide—Rash—Epirubicin—pancreatic cancer	3.09e-05	0.000105	CcSEcCtD
Cyclophosphamide—Dermatitis—Epirubicin—pancreatic cancer	3.09e-05	0.000104	CcSEcCtD
Cyclophosphamide—Headache—Epirubicin—pancreatic cancer	3.08e-05	0.000104	CcSEcCtD
Cyclophosphamide—Dizziness—Doxorubicin—pancreatic cancer	3e-05	0.000101	CcSEcCtD
Cyclophosphamide—Nausea—Epirubicin—pancreatic cancer	2.92e-05	9.85e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Doxorubicin—pancreatic cancer	2.89e-05	9.75e-05	CcSEcCtD
Cyclophosphamide—Rash—Doxorubicin—pancreatic cancer	2.86e-05	9.67e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Doxorubicin—pancreatic cancer	2.86e-05	9.66e-05	CcSEcCtD
Cyclophosphamide—Headache—Doxorubicin—pancreatic cancer	2.85e-05	9.61e-05	CcSEcCtD
Cyclophosphamide—Nausea—Doxorubicin—pancreatic cancer	2.7e-05	9.11e-05	CcSEcCtD
